INDIANAPOLIS, Ind., September 21, 2010 — BioCrossroads today announced the election of Darren Carroll, Vice President – New Ventures, Eli Lilly and Company, to the organization’s Board of Directors.
Carroll has been involved with BioCrossroads’ investment activities as an ―expert volunteer‖ since 2005, chairing the advisory committees for the Indiana Future Fund and the INext Fund, in which Lilly is a significant investor. Carroll is also a member of BioCrossroads’ Indiana Seed Fund I Investment Committee.
Lilly’s New Ventures division includes Lilly Ventures and Lilly Asian Ventures, the first venture capital group of its kind in the pharmaceutical industry. Prior to his current position, Carroll was the founding chief executive officer of InnoCentive, Inc., the first open-innovation business in the physical sciences, which he spun out of Lilly. Among other positions Carroll has held at Lilly, he was the U.S. attorney for Prozac®.
In related actions, the BioCrossroads Board of Directors elected Carroll as an At-Large member of its Executive Committee. Leonard J. Betley, Chairman and President of Richard M. Fairbanks Foundation, Inc., and Regenstrief Foundation, Inc., and Chairman of the Walther Cancer Foundation, Inc., and Jon C. Serbousek, President of Biomet Orthopedics, were also appointed as At-Large members of the BioCrossroads Executive Committee. Other Executive Committee members include Dr. D. Craig Brater, Dean of the Indiana University School of Medicine and BioCrossroads Chair; Mark Miles, President and CEO of the Central Indiana Corporate Partnership, BioCrossroads’ parent organization; and David Johnson, BioCrossroads President and CEO.
“The willingness of great business and community leaders like Darren, Len and Jon to guide the BioCrossroads Board through serving on our Executive Committee is the best possible validation we could have of the importance of the BioCrossroads initiative. The Indiana life sciences community – and the entire State of Indiana – is building a strong base for the future through this brand of distinguished leadership,” Dr. Brater noted.
BioCrossroads (www.biocrossroads.com) is Indiana’s initiative to grow, advance and invest in the life sciences, a public-private collaboration that supports the region’s research and corporate strengths while encouraging new business development. BioCrossroads provides money and support to life sciences businesses, launches new life sciences businesses, expands collaboration and partnerships among Indiana’s life science institutions, expands science education and markets Indiana’s life sciences industry.